Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Decongestant produces vasoconstriction within the nasal mucosa through alpha adrenergic receptor activation and hence they are effective in reducing the symptoms of nasal obstruction. However, these agents have no effect on other symptoms like rhinorrhoea, pruritis or sneezing and may be most effective when used in combination with other agents such as antihistamines. There is number of decongestants are available for oral use but most frequently used decongestant is pseudoephedrine. The common side effects of oral decongestant are central nervous system like nervousness, insomnia, irritability and headache.
The Europe nasal decongestant market is witnessing rapid growth during the forecast period of 2021 to 2027. The nasal decongestant is the monotherapy for the common cold and various other breathing illnesses. The dynamic factors such as rising cases of COVID-19 virus is propelling growth of Europe nasal decongestant market. The rising number of otolaryngology examinations have expanded the awareness of decongestion which is also boosting growth of Europe nasal decongestant market. However, complication related to overuse of nasal sprays is hindering growth of Europe nasal decongestant market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the nasal decongestant market. In addition, complete analysis of changes on nasal decongestant expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Europe economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The healthcare and pharmaceutical companies are going through high pressure for drug innovation to treat coronavirus in patients. The invention of vaccines by key players has lowered the pressure on the pharmaceutical companies to launch drugs for the novel infection. However, key players in nasal decongestant market are rising their R&D efforts. Due to these the nasal decongestant market have experienced positive impact during COVID-19 pandemics.
The Europe nasal decongestant market is categorised by product type, application and country.
Based on product type, the Europe nasal decongestant market is segmented into nasal strips, tablets, spray and capsules. In which sprays segment is also contributing in the growth of Europe nasal decongestant market. The rising number of patients suffering from allergic reactions like cold, congestion, sneezing and runny nose is propelling growth of Europe nasal decongestant market. The surge in the use of nasal sprays for decongestion of nose is also boosting growth of Europe nasal decongestant market. The rising prevalence of allergies is also refuelling growth of Europe nasal decongestant market.
Based on application, the Europe nasal decongestant is bifurcated into asthma, cold and nasal allergies. In which nasal allergies is also contributing in the growth of Europe nasal decongestant market. Allergic rhinitis occurs seasonally or year-round. Diagnosis of the nasal allergies comprised of the history taking, examination of the nasal passage and sometimes skin testing. The nasal allergies is characterised by the symptoms such as sneezing, runny nose and red nose along with watery and itchy eyes. The growing cases of allergic rhinitis is also boosting growth of Europe nasal decongestant market.
The Europe nasal decongestant is studied for key countries such as United Kingdom, Germany, France, Italy and Spain. The United Kingdom is anticipated to dominate the market in 2020. The rising population prone to various allergies is propelling growth of Europe nasal decongestant market. The rising economic developments is also boosting growth of Europe nasal decongestant market. The growing research and development is also refuelling growth of Europe nasal decongestant market.
The major key players in nasal decongestant market are 3M, Abbott Laboratories, Adapt Pharma Inc., Aegis Therapeutics Llc, Allergan Plc, Aptargroup Inc., Astrazeneca Plc, Bayer, Becton, Dickinson And Company, Cipla, Glaxosmithkline Plc, Innovus Pharmaceuticals Inc., Johnson & Johnson Services Inc., Meda Pharmaceuticals Inc., Merck & Co., Inc., Mylan N.V, Nastech Pharmaceutical Company Inc., Nidda Healthcare, Novartis Ag, Patrick Parsons, Pfizer Inc., Procter And Gamble, Rugby Laboratories and Sandoz International Gmbh among others.
November 2019, Sandoz announced that it has entered into a binding agreement for the planned acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings Limited. Strengthening position in world’s third largest generics market.
June 2019: AptarGroup, Inc. acquired two pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC. The acquisitions are part of strategy to broaden its portfolio of services which supports pharmaceutical and biotech customers to accelerate their complex product development.
April 2019: Cipla Ltd. acquired 30% Stake in South African's Brandmed For Business Expansion. The Acquisition was carried out to pair the company’s strengths with Brandmed’s innovative, patient-centric approach to healthcare which will enhance Cipla Medpro’s portfolio.
December 2018: Procter & Gamble (P&G) completed the acquisition of Merck’s Consumer Health business. It is intended to improve P&G’s over the counter (OTC) geographic scale brand portfolio and category footprint across 15 markets.
The report analyses the nasal decongestant market based on product type, application and country. The various product type covered in the market are nasal strips, tablets, sprays and capsules. Based on application, the market is segmented into asthma, cold and nasal allergies. The report also analysed the impact of COVID-19 on the nasal decongestant market and it analyses that the healthcare and pharmaceutical companies are going through high pressure for drug innovation to treat coronavirus in patients. The invention of vaccines by key players has lowered the pressure on the pharmaceutical companies to launch drugs for the novel infection. However, key players in nasal decongestant market are rising their R&D efforts. Due to these the nasal decongestant market have experienced positive impact during COVID-19 pandemics. The study also imparts the major key players operating in the market.
Why to buy this report
